Andrew Hantel, MD; Jonathan M. Marron, MD, MPH; Michael Casey, APRN-BC, FNP; et al.
JAMA Oncol. 2021;7(2):199-205. doi:10.1001/jamaoncol.2020.6159
This cross-sectional study examines the implication of US state crisis standards of care guideline recommendations for patients with cancer, including allocation methods, cancer-related categorical exclusions and deprioritizations, and provisions for blood products and palliative care.
Katelyn M. Atkins, MD, PhD; Tafadzwa L. Chaunzwa, MD; Nayan Lamba, MD; et al.
JAMA Oncol. 2021;7(2):206-219. doi:10.1001/jamaoncol.2020.6332
This cohort study examines the doses of cardiac substructure radiation associated with major cardiac adverse events and all-cause mortality in patients with locally advanced non–small cell lung cancer.
Predicting Radiation-Induced Heart Disease and Survival—Is Location the Key?
Carmen Bergom, MD, PhD; David Rayan, DO; Sherry-Ann Brown, MD, PhD
QuanQiu Wang, MS; Nathan A. Berger, MD; Rong Xu, PhD
has active quiz
JAMA Oncol. 2021;7(2):220-227. doi:10.1001/jamaoncol.2020.6178
This case-control study investigates how patients with specific types of cancer are at risk for coronavirus disease 2019 infection and its adverse outcomes and whether there are cancer-specific racial disparities for infection.
N. Jewel Samadder, MD, MSc; Douglas Riegert-Johnson, MD; Lisa Boardman, MD; et al.
JAMA Oncol. 2021;7(2):230-237. doi:10.1001/jamaoncol.2020.6252
This cohort study examines the prevalence of pathogenic germline variants in patients with cancer using a universal testing approach compared with targeted testing based on clinical guidelines and the subsequent uptake of cascade family variant testing.
Areej El-Jawahri, MD; Thomas W. LeBlanc, MD; Alison Kavanaugh, NP; et al.
JAMA Oncol. 2021;7(2):238-245. doi:10.1001/jamaoncol.2020.6343
This randomized clinical trial assesses the effect of integrated palliative and oncology care on patient-reported and end-of-life outcomes in patients with acute myeloid leukemia.
Catherine H. Van Poznak, MD; Joseph M. Unger, PhD; Amy K. Darke, MS; et al.
JAMA Oncol. 2021;7(2):246-254. doi:10.1001/jamaoncol.2020.6353
This cohort study defines the cumulative incidence of osteonecrosis of the jaw at 3 years in patients receiving zoledronic acid for metastatic bone disease from any malignant neoplasm.
Audio Author Interview:
Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases
Hans-Joachim Schmoll, MD, PhD; Lars H. Lindner, PhD; Peter Reichardt, PhD; et al.
JAMA Oncol. 2021;7(2):255-262. doi:10.1001/jamaoncol.2020.6564
This randomized clinical trial examines the efficacy of gemcitabine and pazopanib compared with pazopanib alone for German patients with soft tissue sarcoma.
Junji Zhang, MD; Yuqian Zhao, PhD; Yi Dai, MD; et al.
JAMA Oncol. 2021;7(2):263-270. doi:10.1001/jamaoncol.2020.6575
This randomized clinical trial compares the results of high-risk human papillomavirus testing vs current primary screening approaches, assessing screening performance, cost-effectiveness, and service system capacity within China’s national cervical cancer screening program.
Kevin Kalinsky, MD, MS; Fangxin Hong, PhD; Carolyn K. McCourt, MD; et al.
JAMA Oncol. 2021;7(2):271-278. doi:10.1001/jamaoncol.2020.6741
This nonrandomized trial evaluates the clinical outcomes and safety of capivasertib for patients with an AKT1 E17K-mutated tumor.